Portal Vein Occlusion is a Valuable Predictor for Postoperative Nausea and Vomiting
1 other identifier
observational
380
1 country
1
Brief Summary
Postoperative nausea and vomiting (PONV) is one of the most common and distressing postoperative complications. PONV risk assessment is recommanded to determine the number of medications or strategies for prophylaxis. Many well-known risk factors have been determined. However, no study has explored liver surgery-specific risk factors. This study aims to identify whether there was an association between portal vein occlusion and PONV among patients after liver surgery. Patients diagnosed with liver cancer and undergoing hepatectomy will be prospectively consecutively recruited. All enrolled patients receive PONV assessments within the first 24 postoperative hours. Logistic regression models will be used to investigate the effects of portal vein occlusion and the other variables on the occurrence of PONV in both univariate and multivariate analyses
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Jun 2023
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
May 30, 2023
CompletedFirst Posted
Study publicly available on registry
June 8, 2023
CompletedStudy Start
First participant enrolled
June 15, 2023
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 1, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
August 1, 2023
CompletedApril 8, 2024
April 1, 2024
2 months
May 30, 2023
April 5, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Postoperative nausea and vomiting
PONV will be evaluated on a four-grade scale from 0 (no nausea and no vomiting), 1 (having nausea but no vomiting), 2 (having vomiting without stomach contents ) to 3 (having vomiting with stomach contents).
up to 24 hours
Study Arms (2)
patients with portal vein occlusion
patients without portal vein occlusion
Interventions
this is no intervention
Eligibility Criteria
Patients who are diagnosed with liver cancer and underwent hepatectomy are eligible.
You may qualify if:
- older than 18 years, planned admissions and elective surgery, and staying at least 24 hours in the surgical unit
You may not qualify if:
- patients with cognitive impairment and patients who have nausea and vomiting related to other existing diseases, such as gastroesophageal reflux disease.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Fudan University Fudan University
Shanghai, Shanghai Municipality, 200032, China
Related Publications (1)
Chen X, Zhao WJ, Yu J, Zhou H, Shi Y, Gao J, Zhang Y. Duration of hepatic portal occlusion is a valuable predictor for postoperative nausea and vomiting in patients underwent liver resection for liver cancer. BMC Cancer. 2025 Jul 16;25(1):1177. doi: 10.1186/s12885-025-14592-0.
PMID: 40670918DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 30, 2023
First Posted
June 8, 2023
Study Start
June 15, 2023
Primary Completion
August 1, 2023
Study Completion
August 1, 2023
Last Updated
April 8, 2024
Record last verified: 2024-04
Data Sharing
- IPD Sharing
- Will not share